OrthoTrophix, Inc.

OrthoTrophix has demonstrated excellent safety, robust improvements of knee function and pain, as well as evidence of disease modification in a broad range of knee osteoarthritis patients in Phase 2 clinical studies of the company's lead therapeutic drug candidate. The overall clinical data strongly suggest delaying or even arresting of the advancement of knee OA, which leads to delay and/or elimination of the needs for knee replacement surgeries. OrthoTrophix controls all relevant IPs and seek corporate partnering and financing on the late stage development of this project.